Eli Lil­ly shares take a hit as com­pa­ny low­ers full-year fore­cast

The roll­out of Covid-19 vac­cines and the de­ci­sion to halt dis­tri­b­u­tion of its an­ti­body ther­a­py has left Eli Lil­ly with some dis­ap­point­ing news to share.

On Tues­day, the com­pa­ny re­port­ed that it missed an­a­lysts’ ex­pec­ta­tions for Q1 prof­its and cut the top end of its full-year fore­cast by about $400 mil­lion. As a re­sult, its stock $LLY dipped about 3.38% on Tues­day morn­ing, pric­ing in around $180 per share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER